Drug Profile
Research programme: coronavirus antisense therapy - Isis/ITRI
Alternative Names: Coronavirus antisense therapy research programme - Isis/ITRI; SARS virus antisense therapy research programme - Isis/ITRILatest Information Update: 16 Jun 2006
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense elements
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 04 Jul 2003 Preclinical trials in Severe acute respiratory syndrome in USA (IV)
- 04 Jul 2003 Preclinical trials in Severe acute respiratory syndrome in USA (unspecified route)